Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 133-137

  Burton, Jeffrey R ^a,b,c   Burton, Ilene ^d   Pearson, Glen J ^a,c,e,f  

^a Faculty of Medicine and Dentistry   (Canada)

^b Divisions of Cardiology and Transplant   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e Cardiac Transplant Clinic   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cyclosporine; Heart transplant; Hydroxymethylglutaryl coenzyme A reductase inhibitor; Rhabdomyolysis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; AZATHIOPRINE; BEZAFIBRATE; CLOPIDOGREL; CYCLOSPORIN; CYTOCHROME P450 3A4; EZETIMIBE; FENOFIBRATE; LISINOPRIL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PREDNISONE; SIMVASTATIN;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CASE REPORT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECHALLENGE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HUMAN; MYALGIA; MYOGLOBINURIA; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; RHABDOMYOLYSIS; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; WEAKNESS;

CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HEART TRANSPLANTATION; HUMANS; MIDDLE AGED; RHABDOMYOLYSIS; SIMVASTATIN; TICLOPIDINE;

EID: 33846420630     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H394     Document Type: Article

References (26)

1. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient, part I: cardiac rejection and immunosuppressive drugs. Circulation 2004;110:3734-40. DOI 10.1161/01.CIR.0000147945.83186.89
2. Page RL II, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient, part IV: drug-drug interactions. Circulation 2005;111:230-9. DOI 10.1161/01.CIR.000051805.86933.35
3. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after heart transplantation. N Engl J Med 1995;333:621-7.
4. Kobashigawa JA, Moriguc JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005;24:1736-40.
5. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four year randomized trial. Circulation 1997;96:1398-402.
6. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003;107:93-7. DOI 101161/01.CIR.0000043241.32523 EE
7. Ross H, Hendry P. Dipchand A, et al. 2001 Canadian Cardiovascular Society Consensus Conference on cardiac transplantation. Can J Cardiol 2003;19:1-35.
8. de Denus S, Al-Jazairi A, Loh E, Jessup M, Stanek EJ, Spinier SA. Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients. Ann Pharmacother 2004;38:1136-41. Epub 18 May 2004. DOI 10.1345/aph.1D535
9. Rodriguez JA, Crespo-Leiro MG, Paniagua MJ, et al. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Transplant Proc 1999;31:2522-3.
10. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95. DOI 10.1345/aph.1A289
11. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003;63:367-78.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-75. DOI 10.1161/CIRCULATIONAHA.105.170815
13. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(suppl III):III-50-III-57. DOI 10.1161/01.CIR.0000131519.15067
14. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9.
15. Kim R. Drugs as p-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34:47-54.
16. Horn JR, Hansten PD. Do statins inhibit clopidogrel's antiplatelet activity? Pharm Times 2003;10:1-2. www.hanstenandhorn.com/hh-article10-03.pdf (accessed 2006 Mar 23).
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
18. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003;107:32-7. DOI 10.1161/01.CIR.0000047060.60595.CC
19. Neubauer H, Günesdogan B, Hanefeld C, Spieker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 2003;24:1744-9.
20. Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol 205;96:103-10.
21. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4. DOI 10.1161/01.CIR.0000088780.57432.43
22. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285-8.
23. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7.
24. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005;91:23-6.
25. Uber PA, Mehra MR, Park MH, Scott RL. Clopidogrel and rhabdomyolysis after heart transplantation (letter). J Heart Lung Transplant 2003;22:107-8.
26. Bader FM, Kfoury AG, Gilbert EM,et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant 2006;25:298-301.